A heterozygous variant in the human cardiac miR-133 gene, MIR133A2, alters miRNA duplex processing and strand abundance
- Monique Ohanian†1,
- David T Humphreys†2, 3,
- Elizabeth Anderson4,
- Thomas Preiss5 and
- Diane Fatkin1, 2, 3, 6Email author
© Ohanian et al; licensee BioMed Central Ltd. 2013
Received: 28 August 2012
Accepted: 27 February 2013
Published: 6 March 2013
MicroRNAs (miRNAs) are small non-coding RNAs that post-transcriptionally regulate gene expression. Sequential cleavage of miRNA precursors results in a ~22 nucleotide duplex of which one strand, the mature miRNA, is typically loaded into the RNA-induced silencing complex (RISC) while the passenger strand is degraded. Very little is known about how genetic variation might affect miRNA biogenesis and function.
We re-sequenced the MIR1-1, MIR1-2, MIR133A1, MIR133A2, and MIR133B genes, that encode the cardiac-enriched miRNAs, miR-1 and miR-133, in 120 individuals with familial atrial fibrillation and identified 10 variants, including a novel 79T > C MIR133A2 substitution. This variant lies within the duplex at the 3′ end of the mature strand, miR-133a-3p, and is predicted to prevent base-pairing and weaken thermostability at this site, favoring incorporation of the passenger strand, miR-133a-5p, into RISC. Genomic DNA fragments containing miR-133a-2 precursor sequences with 79T and 79C alleles were transfected into HeLa cells. On Northern blotting the 79T allele showed strong expression of miR-133a-3p with weak expression of miR-133a-5p. In contrast, the 79C allele had no effect on miR-133a-3p but there was a significant increase (mean 3.6-fold) in miR-133a-5p levels. Deep sequencing of small RNA libraries prepared from normal human and murine atria confirmed that nearly all the mature miR-133a was comprised of miR-133a-3p and that levels of miR-133a-5p were very low. A number of isomiRs with variations at 5′ and 3′ ends were identified for both miR-133a-3p and miR-133a-5p, with 2 predominant miR-133a-3p isomiRs and one predominant miR-133a-5p isomiR. Bioinformatics analyses indicate that the major miR-133a-3p and 5p isomiRs have numerous predicted target mRNAs, only a few of which are in common.
Multiple miR-133a isomiRs with potential different mRNA target profiles are present in the atrium in humans and mice. We identified a human 79T > C MIR133A2 variant that alters miRNA processing and results in accumulation of the miR-133a-5p strand that is usually degraded.
KeywordsMicroRNA isomiR Genetics Atrial fibrillation
MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression. They act by binding to the 3′untranslated regions of target mRNAs and typically reduce mRNA levels by inhibiting translation or stimulating mRNA decay . MiRBase v18  lists 2148 human miRNAs, each of which is expected to have multiple mRNA targets. Consequently, miRNAs can orchestrate suites of changes in gene expression and have been implicated in diverse normal physiological processes and disease states .
Most miRNAs are transcribed from their own genes by RNA polymerase II. A minority of miRNAs are located within introns of other genes and are co-transcribed with the host gene. In the canonical miRNA biosynthesis pathway, primary miRNA (pri-miRNA) hairpins are cleaved by the nuclear RNAase III-type endonuclease Drosha to yield a ~70 nucleotide (nt) precursor miRNA (pre-miRNA) that is then exported to the cytoplasm. Further cleavage of this stem-loop structure y Dicer generates a ~ 22 nt mature miRNA duplex . Typically, the dominant (mature) strand of the duplex is incorporated into an RNA-induced silencing complex (RISC) that binds to the target mRNA by sequence-specific interactions between the “seed” region (nt 2–8) at the 5′ end of the miRNA and the cognate mRNA binding site. The remaining (passenger) strand of the duplex is thought to be non-functional and degraded. Recent deep sequencing data have revealed surprising additional complexity of miRNA processing and have found that multiple miRNA isoforms (isomiRs) of varying sequence composition and length may be present [5–8].
The muscle-enriched miRNAs, miR-1 and miR-133, are amongst the most abundant of the miRNAs present in the normal heart [9, 10]. Two genes, MIR1-1 and MIR1-2, encode miR-1-1 and miR-1-2, while three genes, MIR133A1, MIR133A2, and MIR133B, encode miR-133a-1, miR-133a-2, and miR-133b, respectively. MiR-133a-1 and miR-133a-2 have identical mature sequences, with miR-133b differing only by a single nt at the 3′ end. In humans, MIR1-1 and MIR133A2 are located on chromosome 20 while MIR1-2 and MIR133A1 are located on chromosome 18. These 2 pairs of genes are co-regulated and expressed as bicistronic transcripts. MIR133B is on chromosome 6 and is paired with another muscle-specific miRNA gene, MIR206. Verified mRNA targets of miR-1 and miR-133 include those encoding proteins that are involved in cardiac development, ion channel function, hypertrophy, and fibrosis [11–16].
Atrial fibrillation (AF) is the most common cardiac arrhythmia and a frequent complication of diverse cardiac and systemic disorders. Altered levels of miR-1 and miR-133 have been observed in atrial tissue samples from patients with AF in several studies [17–19]. MiRNA-induced gene expression changes in the atrium could either have a primary role in initiation of AF or contribute to electrical and structural remodelling that perpetuates AF. In this study, we hypothesized that genetic variation could alter the functional effects of miR-1 and miR-133 and contribute to AF pathogenesis. To test this hypothesis, we performed genetic screening of the MIR1-1, MIR1-2, MIR133A1, MIR133A2, and MIR133B genes in a cohort of probands with suspected familial AF. A number of variants were identified, including a novel MIR133A2 variant that was functionally characterized and found to alter miR-133a duplex processing. To assess the potential effects of this variant, we first needed to catalogue the abundance and diversity of miR-133a isomiRs in the normal heart. Deep sequencing of human and murine atrial tissue was performed and revealed an unexpected diversity of miR-133a isomiRs, with nearly all the miR-133a tags comprised of the 2 major miR-133a-3p isomiRs and <1% comprised of miR-133a-5p species. Our data suggest that the MIR133A2 variant increases the relative abundance of miR-133a-5p.
MiR-1 and miR-133 sequence variants
MiR-1 and miR-133 gene variants identified in familial AF probands
Minor allele frequencyb
−43C > T
+15A > G
+74T > C
−102G > A
−82G > A
−19G > A
79T > C
+47T > C
+69G > A
79T > C MIR133A2 variant increases levels of miR-133a-5p
The 79T > C MIR133A2 variant is positioned directly adjacent to the Drosha cleavage site in the stem-loop structure at the 3′ end of miR-133a-3p (Figure 1C). In the absence of sequence data for human miR-133a-5p in miRBase, this location was initially deduced from 3p dominant processed sequence listed for mouse. We predicted that the mismatch introduced by the 79T > C substitution would alter secondary structure and thus precursor processing and/or subsequent strand selection. To test these predictions, we prepared two constructs that replicated the 79T and 79C genotypes of mature miR-133a, transfected these into the HeLa cell line that does not detectably express endogenous miR-133a and performed Northern blotting. For these studies, the miR-133a-2 haplotype (−19G > A, +47T > C), which was present in the proband, II-5, and her affected sister, II-4, was used as the background sequence. The 79T allele had strong expression of miR-133a-3p with low amounts of miR-133a-5p. When compared with 79T, the 79C allele showed no significant change in miR-133a-3p (P = 0.81) but there was a mean 3.6-fold increase in levels of miR-133a-5p (P = 0.003, Figure 1D).
MiR-133a populations in the normal atrium
MiR-133a mRNA target profiles
There are two major outcomes of this study. First, we have characterized atrial miR-133a species and find an extraordinary diversity of 5′ and 3′ miR-133a-3p and miR-133a-5p isomiRs, with two major 3p isomiRs and one major 5p isomiR in both human and mouse. These isomiRs have minimally-overlapping suites of predicted mRNA targets and functions, which suggests that they have distinct biological roles. Second, we report a novel MIR133A2 variant that alters strand abundance during miRNA processing and results in accumulation of miR-133a-5p. This variant is one of only a very few functional miRNA gene variants reported to date.
Despite the enormous interest in miRNAs as master regulators of gene expression, the role of genetic variation is incompletely understood. Single nucleotide polymorphisms (SNPs) in predicted miRNA binding sites on target mRNAs occur frequently and some of these have been associated with phenotypic traits [22–25]. In contrast, SNPs in the miRNA genes themselves are far less common. Several SNPs in pri-miRNA and pre-miRNA have been functional evaluated and shown to result in defective processing and reduced levels of mature miRNA. SNPs are rarely seen (<1%) in the seed regions that are crucially required for target recognition . These observations have provided an argument for strong selective constraint and suggest that seed variants would have substantial effects. The discovery of point mutations in the seed region of miR-96 in two families with nonsyndromic progressive hearing loss provided the first example of human Mendelian disease associated with a miRNA gene variant . Functional SNPs can occur in mature miRNAs outside the seed region, as recently demonstrated by the finding of a rare variant at nt 17 of miR-499 . Evaluation of the effects of this variant in transgenic mice showed that it protected against the cardiomyopathy that developed with overexpression of the wildtype form of miR-499. Here we describe a MIR133A2 variant located in the mature miRNA outside the seed region that changes the way that the miRNA duplex is processed.
MiRNA processing is conventionally assumed to yield only one functional mature miRNA with the passenger strand being degraded and hence, functionally irrelevant. It has recently been appreciated however, that passenger forms are not always selected for degradation, rather, that both 3p and 5p strands of the miRNA duplex may be simultaneously present and that their ratio can be regulated in a tissue- or development-specific manner, suggesting that both strands have inherent functional activity . Here we find that both (mature) miR-133a-3p and (passenger) miR-133a-5p are present in the atrium in humans and mice, with miR-133a-5p normally representing <1% of all miR-133a species. The main effect of the 79T > C MIR133A2 variant is to alter the relative ratio of miR-133a-3p and 5p strands.
Current models posit that the strand of the miRNA duplex with weaker base-pairing at the 5′ end is preferentially incorporated into RISC . If the conventional murine miR-133a-5p sequence as annotated by miRBase (v18) represented the predominant isomiR in the normal human heart, then the nt corresponding to position 79 would lie just outside the base-paired region of the processed miRNA duplex. However, our deep sequencing data clearly show that the −1 isomiR is the most abundant miR-133a-5p species in the human atrium. Consequently, the 79T > C variant lies within the duplex and would directly prevent base-pairing and weaken thermostability at this site, favoring incorporation of miR-133a-5p into RISC. Additionally the lack of base pairing at position 79C is likely to enlarge the bulge in the stem-loop structure, a feature known to influence positional cleavage by Dicer and Drosha and result in increased variability of 5′ isomiRs [8, 29]. The canonical miRNA biosynthesis pathway predicts 3p and 5p miRNAs of 22 nt in length, but deep sequencing studies have revealed a surprising extent of isomiR diversity in most tissues and species [5–8]. These isomiRs may include 5′ or 3′ cleavage variations, and non-templated additions or trimming at the 3′ end. It has been found that the relative abundance and types of isomiRs in specific tissues can vary over time and with disease states, suggesting that they have distinctive biological functions [5, 8, 30].
It is conventionally assumed that the seed regions are the major determinants of target specificity, and thus it is plausible that 5′ isomiR variation can affect mRNA target selection. For example, our group has recently demonstrated that the two most abundant miR-133a isomiRs in murine atrial HL-1 cells have different targeting properties . Given that each isomiR has hundreds of mRNA targets, dynamic fluxes in isomiR characteristics may give rise to an unexpected complexity of miRNA:mRNA interactions and provide a mechanism for intricate regulation of gene expression in specific tissues. To assess the potential impact of the 79T > C MIR133A2 variant, we searched for differences in miR-133a-3p and miR-133a-5p predicted mRNA targets using the respective human and murine seed regions and a set of genes known to be differentially regulated in miR-133a knockout mice . These results showed that only a minority of predicted miR-133a targets were shared, and that most were unique to either 3p or 5p forms. With the 79T > C MIR133A2 variant, no changes in miR-133a-3p target gene expression would be expected. In contrast, the relative increase in miR-133a-5p could have a relatively greater impact and give rise to selective repression of the 5p suite of targets. It is notable that at least 25% of the lowest-abundance miR-133a-5p targets include mRNAs involved in regulation of transcription, signaling and membrane transport. Further studies are required to determine whether changes in miR-133a-5p directly alter levels of these critical molecules and have biologically-significant functional effects.
The relationship, if any, between the 79T > C MIR133A2 variant and AF in the Family KB proband is questionable. Although DNA samples were unavailable from the deceased parents, it seems most likely that the 79 T > C substitution is a de novo sequence change which was uniquely present in one family member. A causal gene mutation that can account for the familial pattern of AF in this kindred has yet to be identified. The presence of the MIR133A2 variant in the Family KB proband could foreseeably have a modifying effect by altering gene expression profiles in the atrium. A number of factors in addition to genetic variation need to be considered in this individual, including the impact of AF per se and of co-existent risk factors for AF. Altered expression of miR-133 itself has been observed in cardiac tissues from patients with AF [18, 19], and conditions that predispose to AF, such as atrial dilation, ventricular hypertrophy, and myocardial ischemia [12, 31]. It is notable that individual II-5 had both hypertension and valvular heart disease which independently increase AF risk. A limitation of this study is the lack of atrial tissue samples to document gene expression patterns in 79T and 79C family members. The collective effects of the multiple variables present in individual II-5 on atrial gene expression and the electrical and structural properties of the atrial wall are difficult to predict and could promote or protect against AF.
MiRNA duplex processing generates a dominant strand that is incorporated into RISC and a passenger strand that is usually degraded. In the normal human atrium, almost all the miR-133a is comprised of miR-133a-3p with negligible amounts of miR-133a-5p. Although multiple 5′ and 3′ isomiRs are present, there are only 2 major miR-133a-3p isomiRs and one major miR-133a-5p isomiR. These isomiRs have distinctive suites of predicted gene targets suggesting independent biological roles. Very few genetic variants in mature miRNA sequences have been reported and functionally characterized. We have identified a missense MIR133A2 variant that alters miR-133a duplex processing and strand abundance with accumulation of miR-133a-5p in HeLa cells. Further studies to confirm these findings and to document mRNA expression profiles in patient heart tissues are indicated. Despite the importance of miR-133a in atrial biology, miR-133a genetic variants are not a common cause of familial AF.
Genetics study subjects
One hundred and twenty subjects with suspected familial AF were identified from St Vincent’s Hospital and by physician referral. Family probands and their relatives were evaluated by medical history and physical examination, 12-lead echocardiography and transthoracic echocardiography. A positive family history was defined as the presence of documented AF in 2 or more first-degree family members. Two hundred and fifty healthy individuals with no history of cardiovascular disease comprised a control group. All families and control subjects were of Western European background. Genomic DNA was isolated from whole blood samples using the standard salting-out technique. Informed, written consent was obtained from all participants and protocols were approved by the St Vincent’s Hospital campus human and animal research ethics committees.
Primer sequences used for PCR amplification and sequencing
Amplicon size (bp)
5′- gagatggattcagggatgga -3′
5′- acctgctgacacaggcaaag -3′
5′- ggaaccattaatgccatgct -3′
5′- tgaaatctacttcactggatcttctt -3′
5′- tttaaaccattaagcgcagga -3′
5′- ttgaaatccttaagtcatccataca -3′
5′- ctgcagagcttgagggaaac -3′
5′- caaggaggaacaagcaggag -3′
5′- agtcatgcaacatgaaatacaaa -3′
5′- gagtgcaaaggcacagaaca -3′
Plasmid constructs and cell transfections
A 272bp fragment containing the precursor sequence of mature miR-133a-2 with 79T and 79C alleles was amplified from genomic DNA using gene-specific primers containing BamHI and HindIII restriction enzyme sites (underlined): forward: 5′- ggggcggccgcggatccatctccatcgggactgc -3′, reverse: 5′- gggaagcttggcactcagggcttcactta -3′. Amplification was carried out using FastStart Taq DNA Polymerase with the same cycling condictions as described for MIR1-1, MIR133A2 and MIR133B above. PCR amplicons were purified using the QIAquick Gel Extraction Kit (Qiagen, Hildem, Germany) and cloned into the pGEM®-T Easy Vector system (Promega, Fitchburg, WI, USA) according to manufacturer’s instructions. Clones were digested with BamHI and HindIII and ligated to BamHI- and HindIII-digested pSilencerTM puro 4.1-CMV vector (Applied Biosystems). All plasmid constructs were confirmed by sequencing.
HeLa cells (ATCC, Manassas, VA, USA) were maintained in Dulbecco’s modified eagle medium (DMEM) with 5% fetal calf serum, supplemented with glutamine and penicillin-streptomycin. Cells were seeded in a 6-well plate 8 hours before transfection. Transfections were performed in duplicate at ~70% confluency by adding 1.5mL of DMEM and 1mL of transfection solution per well. The 1mL transfection solution contained Opti-MEM®, 150ng of 79T or 79C constructs and 5uL of Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA, USA), which was incubated for 20 minutes at room temperature prior to transfection.
HeLa cells (ATCC) were harvested after 24 hours and total RNA was extracted using TRIzol® (Invitrogen). Total RNA (5ug) was separated on 5% stacking/12% resolving polyacrylamide gels, transferred electrophoretically to Gene Screen Plus® Hybridization Transfer Membranes (Perkin Elmer, Waltham, MA, USA). Separated RNA was fixed on the membranes by ~20 sec UV crosslinking on a UV Stratalinker 2400 (Stratagene, Santa Clara, Ca, USA). Northern blotting was performed as described . DNA oligonucleotide probes (5′- tacagctggttgaaggggaccaaa -3′, 5′- gatttggttccattttaccagct -3′, 5′- tgtgctgccgaagcaagcac -3′) complementary to mature miR-133a (miR-133a-3p), passenger miR-133a (miR-133a-5p) and U6 sequences, respectively, were end-labeled with 32P using T4 Polynucleotide Kinase (New England Biolabs, Ipswich, MA, USA) and purified by Microspin G-25 columns (GE Healthcare) according to manufacturer’s instructions. A single probe was incubated with the membrane in hybridization buffer (250mM NaPO4, 7% SDS, pH 7) at 42°C overnight. After hybridization, membranes were washed 3 times with 2xSSC (1.753% NaCl, 0.882% Na3C6H5O7) at 42°C, and exposed overnight. Phosphorimaging was performed on a Fuji imager (FLA-5100, Fujifilm, Minato-ku, Tokyo, Japan). Hybridization signals were quantified using Multi Gauge v2.3 software (Fujifilm, Minato-ku, Tokyo, Japan) and the values measured for each probe from each blot were scaled to the average signal. The scaled miR-133a values were then normalized to the scaled U6 values to adjust for any loading bias. Statistical analyses were performed using the Mann–Whitney U test with a P value <0.05 deemed significant.
For deep sequencing of atrial myocardium, total RNA was extracted using the miRNeasy® Kit (QIAGEN, Hildem, Germany) from right atrial appendage samples obtained from two males aged 62 and 64 years with no history of AF who underwent coronary artery bypass graft surgery. Atrial tissue was also obtained from the hearts of 3 wild-type mice aged 4–6 weeks. Small RNA libraries were created using NEBNext® small RNA library preparation kit (New England Biolabs, Ipswich, MA, USA) and sequenced on a 5500 SOLiDTM platform (Applied Biosystems). Sequencing data were mapped using Lifescope software (Applied Biosystems). Processed miRNA counts were initially collated from all tags that aligned within 3 nt of the miRBase defined 5′ starting position. Tags that mapped to miRBAse v18 can be accessed via a “miRDSPRing” document (D. Humphreys, manuscript in preparation) and are available in the Supporting Information (Tables S1 and S2).
MiRNA target predictions
Gene targets for human and murine miR133a were predicted using TargetScan Custom (v5.2)  with the “seeds” (nt 2–8) of the most abundant miR-133a-3p and miR-133a-5p isomiRs that were identified via deep sequencing used as inputs. The newer version of TargetsScan (v6.2) and a range of other commonly-used publically-available target prediction programs (DIANA-microT, Microinspector, microRNA.org, MirTarget2, PicTar, PITA, RNA22, RNAhybrid) were unable to be utilized because human and/or murine miR-133a-5p sequences were unable to be inputted and/or analyzed. Predicted gene targets of murine miR-133a were matched against mRNAs that in which expression levels were altered by at least 1.5 fold in microarray data from miR-133a knockout mice . The TargetScan outputs for human miR-133a-3p and miR-133a-5p were imported into Ingenuity Pathway Analysis software (Ingenuity® Systems, http://www.ingenuity.com) for identification of biological pathways in the heart that might be differentially regulated (Additional file 5: Table S5).
Dulbecco’s modified eagle medium
Polymerase chain reaction
RNA-induced silencing complex
We thank collaborating physicians for proband referrals; Poonam Zodgekar and Kathryn Stockhammer, for family member recruitment; Gunjan Trivedi and Lena Soka, for laboratory assistance; Kartik Ramesh, Keng Tan, Li Sze Yeo, and Khumud Dhital for collection of atrial tissue samples; Cath Suter, Carly Hynes, and Hardip Patel, for assistance with deep sequencing and miRNA analysis.
- Fabian MR, Sonenberg N, Filipowicz W: Regulation of mRNA translation and stability by microRNAs. Annu Rev Biochem. 2010, 79: 351-379. 10.1146/annurev-biochem-060308-103103.View ArticlePubMed
- Kozomara A, Griffiths-Jones S: miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res. 2011, 39 (Suppl 1): D152-D157.PubMed CentralView ArticlePubMed
- Mendell JT, Olson EN: MicroRNAs in stress signaling and human disease. Cell. 2012, 148: 1172-1187. 10.1016/j.cell.2012.02.005.PubMed CentralView ArticlePubMed
- Winter J, Jung S, Keller S, Gregory RI, Diederichs S: Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol. 2009, 11: 228-234. 10.1038/ncb0309-228.View ArticlePubMed
- Fernandez-Valverde SL, Taft RJ, Mattick JS: Dynamic isomiR regulation in Drosophila development. RNA. 2010, 16: 1881-1888. 10.1261/rna.2379610.PubMed CentralView ArticlePubMed
- Lee LW, Zhang S, Etheridge A, Ma L, Martin D, Galas D, Wang K: Complexity of the microRNA repertoire revealed by next-generation sequencing. RNA. 2010, 16: 2170-2180. 10.1261/rna.2225110.PubMed CentralView ArticlePubMed
- Cloonan N, Wani S, Xu Q, Gu J, Lea K, Heater S, Barbacioru C, Steptoe AL, Martin HC, Nourbaksh E, Krishnan K, Gardiner B, Wang X, Nones K, Steen JA, Matigian NA, Wood DL, Kassahn KS, Waddell N, Shepherd J, Lee C, Ichikawa J, McKernan K, Bramlett K, Kuersten S, Grimmond SM: MicroRNAs and their isomiRs function cooperatively to target common biological pathways. Genome Biol. 2011, 12: R126-10.1186/gb-2011-12-12-r126.PubMed CentralView ArticlePubMed
- Humphreys DT, Hynes CJ, Patel HR, Wei GH, Cannon L, Fatkin D, Suter CM, Clancy JL, Preiss T: Complexity of murine cardiomyocyte miRNA biogenesis, sequence variant expression and function. PLoS One. 2012, 7: e30933-10.1371/journal.pone.0030933.PubMed CentralView ArticlePubMed
- Liang Y, Ridzon D, Wong L, Chen C: Characterization of microRNA expression in normal human tissues. BMC Genomics. 2007, 8: 166-10.1186/1471-2164-8-166.PubMed CentralView ArticlePubMed
- Luo X, Zhang H, Xiao J, Wang Z: Regulation of human cardiac ion channel genes by microRNAs: theoretical perspective and pathophysiological implications. Cell Physiol Biochem. 2010, 25: 571-586. 10.1159/000315076.View ArticlePubMed
- Zhao Y, Ransom JF, Li A, Vedantham V, Von Drehle M, Muth AN, Tsuchihashi T, McManus MT, Schwartz RJ, Srivastava D: Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1-2. Cell. 2007, 129: 303-317. 10.1016/j.cell.2007.03.030.View ArticlePubMed
- Care A, Catalucci D, Felicetti F, Bonci D, Addario A, Gallo P, Bang ML, Segnalini P, Gu Y, Dalton ND, Elia L, Latronico MV, Høydal M, Autore C, Russo MA, Dorn GW, Ellingsen O, Ruiz-Lozano P, Peterson KL, Croce CM, Peschle C, Condorelli G: MicroRNA-133 controls cardiac hypertrophy. Nat Med. 2007, 13: 613-618. 10.1038/nm1582.View ArticlePubMed
- Duisters RF, Tijsen AJ, Schroen B, Leenders JJ, Lentink V, van der Made I, Herias V, Van Leeuwen RE, Schellings MW, Barenbrug F, Maessen JG, Heymans S, Pinto YM, Creemers EE: MiR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling. Circ Res. 2009, 104: 170-178. 10.1161/CIRCRESAHA.108.182535.View ArticlePubMed
- Matkovich SJ, Wang W, Tu Y, Eschenbacher WH, Dorn LE, Condorelli G, Diwan A, Nerboone JM, Dorn GW: MicroRNA-133a protects against myocardial fibrosis and modulates electrical repolarization without affecting hypertrophy in pressure-overloaded adult hearts. Circ Res. 2010, 106: 166-175. 10.1161/CIRCRESAHA.109.202176.PubMed CentralView ArticlePubMed
- Belevych AE, Sansom SE, Terentyeva R, Ho HT, Nishijima Y, Martin MM, Jindal HK, Rochira JA, Kunitomo Y, Abdellatif M, Carnes CA, Elton TS, Györke S, Terentyev D: MicroRNA-1 and-133 increase arrhythmogenesis in heart failure by dissociating phosphatase activity from RyR2 complex. PLoS One. 2011, 6: e28324-10.1371/journal.pone.0028324.PubMed CentralView ArticlePubMed
- Matkovich SJ, Van Booven DJ, Eschenbacher WH, Dorn GW: RISC RNA sequencing for context-specific identification of in vivo microRNA targets. Circ Res. 2011, 108: 18-26. 10.1161/CIRCRESAHA.110.233528.PubMed CentralView ArticlePubMed
- Girmatsion Z, Biliczki P, Bonauer A, Wimmer-Greinecker G, Scherer M, Moritz A, Bukowska A, Goette A, Nattel S, Hohnloser SH, Ehrlich JR: Changes in microRNA-1 expression and IK1 up-regulation in human atrial fibrillation. Heart Rhythm. 2009, 6: 1802-1809. 10.1016/j.hrthm.2009.08.035.View ArticlePubMed
- Xiao J, Liang D, Zhang Y, Liu Y, Zhang H, Liu Y, Li L, Liang X, Sun Y, Chen YH: MicroRNA expression signature in atrial fibrillation with mitral stenosis. Physiol Genomics. 2011, 43: 655-664. 10.1152/physiolgenomics.00139.2010.View ArticlePubMed
- Cooley N, Cowley MJ, Lin RC, Marasco S, Wong C, Kaye DM, Dart AM, Woodcock EA: Influence of atrial fibrillation on microRNA expression profiles in left and right atria from patients with valvular heart disease. Physiol Genomics. 2012, 44: 211-219. 10.1152/physiolgenomics.00111.2011.View ArticlePubMed
- De Mena L, Coto E, Cardo LF, Diaz M, Blazquez M, Ribacoba R, Salvador C, Pastor P, Samaranch L, Moris G, Menéndez M, Corao AI, Alvarez V: Analysis of the Micro-RNA-133 and PITX3 genes in Parkinson’s disease. Am J Med Genet. 2010, 153B: 1234-1239.PubMed
- Liu N, Bezprozvannaya S, Williams AH, Qi X, Richardson JA, Bassel-Duby R, Olson EN: MicroRNA-133a regulates cardiomyocyte proliferation and suppresses smooth muscle gene expression in the heart. Genes Dev. 2008, 22: 3242-3254. 10.1101/gad.1738708.PubMed CentralView ArticlePubMed
- Saunders MA, Liang H, Li WH: Human polymorphism at microRNAs and microRNA target sites. Proc Natl Acad Sci. 2007, 104: 3300-3305. 10.1073/pnas.0611347104.PubMed CentralView ArticlePubMed
- Borel C, Antonarakis SE: Functional genetic variation of human miRNAs and phenotypic consequences. Mamm Genome. 2008, 19: 503-509. 10.1007/s00335-008-9137-6.View ArticlePubMed
- Kim J, Bartel DP: Allelic imbalance sequencing reveals that single-nucleotide polymorphisms frequently alter microRNA-directed repression. Nat Biotechnol. 2009, 27: 472-477. 10.1038/nbt.1540.PubMed CentralView ArticlePubMed
- Ryan BM, Robles AI, Harris CC: Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer. 2010, 10: 389-402. 10.1038/nrc2867.PubMed CentralView ArticlePubMed
- Mencia A, Modamio-Hoybjor S, Redshaw N, Morin M, Mayo-Merino F, Olavarrieta L, Aguirre LA, Del Castillo I, Steel KP, Dalmay T, Moreno F, Moreno-Pelayo MA: Mutations in the seed region of human miR-96 are responsible for nonsyndromic progressive hearing loss. Nat Genet. 2009, 41: 609-613. 10.1038/ng.355.View ArticlePubMed
- Dorn GW, Matkovich SJ, Eschenbacher WH, Zhang Y: A human 3’ miR-499 mutation alters cardiac mRNA targeting and function. Circ Res. 2012, 110: 958-967. 10.1161/CIRCRESAHA.111.260752.PubMed CentralView ArticlePubMed
- Yang JS, Phillips MD, Betel D, Mu P, Ventura A, Siepel AC, Chen KC, Lai EC: Widespread regulatory activity of vertebrate microRNA* species. RNA. 2011, 17: 312-326. 10.1261/rna.2537911.PubMed CentralView ArticlePubMed
- Starega-Roslan J, Krol J, Koscianska E, Kozlowski P, Szlachcic WJ, Sobczak K, Krzyzosiak WJ: Structural basis of miRNA length variety. Nucleic Acids Res. 2011, 39: 257-268. 10.1093/nar/gkq727.PubMed CentralView ArticlePubMed
- Marti E, Pantano L, Banez-Coronel M, Llorens F, Minones-Moyano E, Porta S, Sumoy L, Ferrer I, Estivill X: A myriad of miRNA variants in control and Huntington’s disease brain regions detected by massively parallel sequencing. Nucleic Acids Res. 2010, 38: 7219-7235. 10.1093/nar/gkq575.PubMed CentralView ArticlePubMed
- Bostjancic E, Zidar N, Stajer D, Glavac D: MicroRNAs miR-1, miR-133a, miR-133b, and miR-208 are dysregulated in human myocardial infarction. Cardiology. 2010, 115: 163-169. 10.1159/000268088.View ArticlePubMed
- Beilharz TH, Humphreys DT, Clancy JL, Thermann R, Martin DI, Hentze MW, Preiss T: MicroRNA-mediated messenger RNA deadenylation contributes to translational repression in mammalian cells. PLoS One. 2009, 4: e6783-10.1371/journal.pone.0006783.PubMed CentralView ArticlePubMed
- Lewis BP, Burge CB, Bartel DP: Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005, 120: 15-20. 10.1016/j.cell.2004.12.035.View ArticlePubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.